PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multice

695 adults and children with and without HIV infection were recruited from three centres in South Africa and Botswana for a study of human parvovirus 4 (PARV4). Data includes cohort descriptors, PCR primers, overlapping peptides for ELISpot assays, and screening results from 14 PARV4 IgG-positive subjects. Ethics approval was granted by multiple institutional review boards including the University of KwaZulu-Natal and Oxford Research Ethics Committee.

Use Cases

• Analyze PARV4 prevalence and co-infection patterns based on cohort descriptors and screening results.
• Study immune responses to PARV4 based on IFN-gamma ELISpot assay results using overlapping peptides.
• Investigate associations between HIV status and PARV4 infection based on IgG and PCR data.
• Design PCR screening protocols based on the provided primer sequences for HCV and PARV4.

Strengths

• Data from a multi-centre cohort of 695 individuals provides a substantial sample size.
• Includes multiple data types: cohort descriptors, laboratory primers, peptide panels, and assay results.
• Ethics approval from multiple international and local review boards suggests rigorous oversight.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

Colin Sharp, via paperswithcode.

Collection Method

Compiled from three clinical centres by recruiting adults and children, with screening via IgG, PCR, and ELISpot assays.

Geography

Southern Africa (Kimberley and Durban, South Africa; Gaborone, Botswana).